BackEuropean Biotech Acquisition - Warrants (06/03/2026) Overview
European Biotech Acquisition Corp - Warrants (06/03/2026)

European Biotech Acquisition - Warrants (06/03/2026) P/E Ratio

European Biotech Acquisition - Warrants (06/03/2026) (EBACW) has a P/E ratio of 41.44, above the sector sector average of 33.83.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

41.44

P/E Ratio

41.44

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

European Biotech Acquisition - Warrants (06/03/2026) (EBACW) FAQ

European Biotech Acquisition - Warrants (06/03/2026)'s p/e ratio stands at 41.44. That is above the sector sector average of 33.83. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

European Biotech Acquisition - Warrants (06/03/2026) sits higher the its sector benchmark (33.83) with a P/E ratio of 41.44. That is roughly 22.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 41.44 is attractive depends on European Biotech Acquisition - Warrants (06/03/2026)'s earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how European Biotech Acquisition - Warrants (06/03/2026)'s P/E ratio evolved across reporting periods, while the comparison chart places EBACW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.